Filtered By:
Condition: Disability
Cancer: Cancer

This page shows you your search results in order of relevance. This is page number 3.

Order by Relevance | Date

Total 287 results found since Jan 2013.

Neuroprotective Strategies for Stroke by Natural Products: Advances and Perspectives
Curr Neuropharmacol. 2023 Jul 17. doi: 10.2174/1570159X21666230717144752. Online ahead of print.ABSTRACTCerebral ischemic stroke is a disease with high prevalence and incidence. Its management focuses on rapid reperfusion with intravenous thrombolysis and endovascular thrombectomy. Both therapeutic strategies reduce disability, but the therapy time window is short, and the risk of bleeding is high. Natural products (NPs) have played a key role in drug discovery, especially for cancer and infectious diseases. However, they have made little progress in clinical translation and pose challenges to the treatment of stroke. Rece...
Source: Current Neuropharmacology - July 17, 2023 Category: Drugs & Pharmacology Authors: Aifen Liu Jingyan Hu Tzu-Shao Yeh Chengniu Wang Jilong Tang Xiaohong Huang Bin Chen Liexiang Huangfu Weili Yu Lei Zhang Source Type: research

Medicinal plants against ischemic stroke.
Abstract Ischemic stroke is one of the major causes of global deaths. Prominent changes in the Central Nervous System (CNS) are observable including emotional, cognitive and behavioural changes during the recovery phase of a stroke. Brain ischemia affects a large portion of patients across the world with permanent disability or death. During the ischemic stroke onset, apart from inducing brain damage, existing microglial cells, immune cells, inflammatory factors such as chemokines and cytokines affect the process of brain repair. For the reduction of this damage, there is a need of understanding the basic mechanis...
Source: Current Pharmaceutical Biotechnology - December 9, 2020 Category: Biotechnology Authors: Roy A, Datta S Tags: Curr Pharm Biotechnol Source Type: research

Ferroptosis —A Novel Mechanism With Multifaceted Actions on Stroke
As a neurological disease with high morbidity, disability, and mortality, the pathological mechanism underlying stroke involves complex processes such as neuroinflammation, oxidative stress, apoptosis, autophagy, and excitotoxicity; but the related research on these molecular mechanisms has not been effectively applied in clinical practice. As a form of iron-dependent regulated cell death, ferroptosis was first discovered in the pathological process of cancer, but recent studies have shown that ferroptosis is closely related to the onset and development of stroke. Therefore, a deeper understanding of the relationship betwe...
Source: Frontiers in Neurology - April 11, 2022 Category: Neurology Source Type: research

Novel contact-kinin inhibitor sylvestin targets thromboinflammation and ameliorates ischemic stroke
Cell Mol Life Sci. 2022 Apr 13;79(5):240. doi: 10.1007/s00018-022-04257-7.ABSTRACTIschemic stroke is a leading cause of death and disability worldwide. Increasing evidence indicates that ischemic stroke is a thromboinflammatory disease in which the contact-kinin pathway has a central role by activating pro-coagulant and pro-inflammatory processes. The blocking of distinct members of the contact-kinin pathway is a promising strategy to control ischemic stroke. Here, a plasma kallikrein and active FXII (FXIIa) inhibitor (sylvestin, contained 43 amino acids, with a molecular weight of 4790.4 Da) was first identified from fore...
Source: Cancer Control - April 13, 2022 Category: Cancer & Oncology Authors: Zhiye Zhang Chuanbin Shen Mingqian Fang Yajun Han Chengbo Long Weihui Liu Min Yang Ming Liu Dengdeng Zhang Qiqi Cao Xue Chen Yaqun Fang Qiumin Lu Zongliu Hou Yaxiong Li Zhenze Liu Xi Lei Heyu Ni Ren Lai Source Type: research

Risk factors and predictors for venous thromboembolism in people with ischemic stroke: A systematic review
In conclusion, this systematic review informs on several potential risk factors and predictors for VTE in people with ischemic stroke. To improve risk stratification and guide development of risk prediction models, further confirmation is needed, as there were few high-quality studies on each factor.PMID:35815351 | DOI:10.1111/jth.15813
Source: Thrombosis and Haemostasis - July 11, 2022 Category: Hematology Authors: Birgitte G T øndel V ânia M Morelli John-Bjarne Hansen Sigrid K Braekkan Source Type: research

Identification of the lncRNA-miRNA ‒mRNA regulatory network for middle cerebral artery occlusion-induced ischemic stroke
Front Genet. 2023 May 9;14:1169190. doi: 10.3389/fgene.2023.1169190. eCollection 2023.ABSTRACTStroke known as a neurological disease has significant rates of disability and mortality. Middle cerebral artery occlusion (MCAO) models in rodents is crucial in stroke research to mimic human stroke. Building the mRNA and non-conding RNA network is essential for preventing MCAO-induced ischemic stroke occurrence. Herein, genome-wide mRNA, miRNA, and lncRNA expression profiles among the MCAO group at 3 h, 6 h, and 12 h after surgery and controls using high-throughput RNA sequencing. We detected differentially expressed mRNAs (DE-m...
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Guixin Shi Dong He Hua Xiao Yu'e Liu Chuanyong Liu Fang Cao Source Type: research

An occupational therapy intervention for residents with stroke related disabilities in UK care homes (OTCH): cluster randomised controlled trial.
CONCLUSIONS: This large phase III study provided no evidence of benefit for the provision of a routine occupational therapy service, including staff training, for care home residents living with stroke related disabilities. The established three month individualised course of occupational therapy targeting stroke related disabilities did not have an impact on measures of functional activity, mobility, mood, or health related quality of life, at all observational time points. Providing and targeting ameliorative care in this clinically complex population requires alternative strategies.Trial registration Current Controlled ...
Source: Cancer Control - February 8, 2015 Category: Cancer & Oncology Authors: Sackley CM, Walker MF, Burton CR, Watkins CL, Mant J, Roalfe AK, Wheatley K, Sheehan B, Sharp L, Stant KE, Fletcher-Smith J, Steel K, Wilde K, Irvine L, Peryer G, OTCH trial investigators Tags: BMJ Source Type: research

Stroke Treatment and Prevention
Stroke is the leading cause of permanent disability in the United States (US). Each year approximately 795,000 people suffer from a stroke in the US, now being the number five cause of death behind heart disease, cancer, chronic lower respiratory disease, and accidents. In fact 1 in 20 people die from a stroke.1 In 2013 there were 6.5 million stroke deaths worldwide. On a global basis, stroke is the number two cause of death behind ischemic heart disease.2 The vast majority of strokes are ischemic (87%).
Source: Progress in Cardiovascular Diseases - May 1, 2017 Category: Cardiology Authors: Rajan A.G. Patel, Christopher J. White Tags: Editorial Source Type: research

Understanding History, and Not Repeating It. Neuroprotection for Acute Ischemic Stroke: From Review to Preview
Ischemic stroke is a major cause of morbidity and mortality worldwide. According to the American Heart Association and the National Institute of Neurological Disease and Stroke, an estimated 795,000 Americans suffer a stroke each year, with ∼87% being ischemic [1]. Annually, stroke accounts for over 220,000 deaths, 4th overall behind cardiac disease, cancer, and chronic lower respiratory disease [2]. It is the leading cause of long-term disability in the US, with about ¼ of the survivors needing assistance with activities of daily living six months after their ictus [1].
Source: Clinical Neurology and Neurosurgery - December 2, 2014 Category: Neurosurgery Authors: Stephen Grupke, Jason Hall, Michael Dobbs, Gregory J. Bix, Justin F. Fraser Source Type: research

Acute ischemic stroke and abnormal blood hemoglobin concentration
ConclusionsOur results suggest that an elevated HGB on the initial admission is associated with more severe strokes, greater disability at discharge, and higher 30‐day mortality after AIS. A low HGB on admission is associated with longer stay in the acute care hospital.
Source: Acta Neurologica Scandinavica - October 21, 2015 Category: Neurology Authors: J. C. Furlan, J. Fang, F. L. Silver Tags: Original Article Source Type: research

UK heart disease and stroke death rates now lower than cancer
Conclusion This valuable research informs on the burden of cardiovascular disease and associated mortality across European countries. It demonstrates that CVD is still the most common cause of death across Europe, but rates have been falling over the past 10 years. This fall means that in several European countries, including the UK, cancer rates now overtake CVD death rates in men. Generally, CVD disability and burden of disease seems to be greater in Eastern European countries. The WHO mortality data and population data are quite up-to-date and should be reliable, though as the researchers say, there was a lack of high ...
Source: NHS News Feed - August 15, 2016 Category: Consumer Health News Tags: Heart/lungs Cancer Neurology Source Type: news

A new era in stroke care gives larger treatment window and better outcomes
According to the American Heart/American Stroke Association, stroke affects nearly 800,000 people in the United States each year. It is the fifth leading cause of death, and the leading cause of long-term disability.  It’s also the leading cause of preventable disability. In China it is the leading cause of death surpassing both cancer and heart disease. Stroke occurs when a blood vessel carrying oxygen and nutrients to the brain is either blocked by a blood clot or plaque (ischemic stroke), or…
Source: bizjournals.com Health Care News Headlines - August 15, 2018 Category: Health Management Authors: Alexandria Foley Source Type: news

Monoclonal antibody as an emerging therapy for acute ischemic stroke.
Authors: Woods D, Jiang Q, Chu XP Abstract Acute ischemic stroke (AIS) is the 5th leading cause of death and the leading cause of neurological disability in the United States. The oxygen and glucose deprivation associated with AIS not only leads to neuronal cell death, but also increases the inflammatory response, therefore decreasing the functional outcome of the brain. The only pharmacological intervention approved by the US Federal Food and Drug Administration for treatment of AIS is tissue plasminogen activator (t-PA), however, such treatment can only be given within 4.5 hours of the onset of stroke-like sympto...
Source: International Journal of Physiology, Pathophysiology and Pharmacology - September 18, 2020 Category: Physiology Tags: Int J Physiol Pathophysiol Pharmacol Source Type: research